Aravax’s Phase II peanut allergy trial met its primary endpoint, with younger paediatric patients able to better tolerate peanuts after receiving the company’s drug for 12 months.

The study (NCT05621317) enrolled two cohorts of paediatric patients, the first including patients aged between 12 and 17, and the second including patients aged between four and 11. The older cohort looked at safety of the drug, while the younger cohort also evaluated efficacy.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

In patients aged four to 11, there was a statistically significant difference in the increase in maximum tolerated dose of peanut from baseline to M12 observed in those who received PVX108 50nmol, a monthly intradermal injection, compared to placebo, with a 2.4-fold vs 1.2-fold change in least squares geometric mean, respectively.

There was also a statistically significant reduction in the severity of food challenge reactions, with more than two-thirds (67%) of the adverse reactions to the baseline reactive dose of the food challenge being graded zero or mild after treatment with PVX108 compared to 35% in the placebo cohort.

After 12 months, 39.4% of patients treated with PVX108 50nmol tolerated a cumulative dose of ≥ 443mg peanut protein, while this endpoint was achieved by 16.7% in the placebo group.

Peanut skin prick test reactions were also significantly improved following PVX108 treatment compared to placebo.

The drug was well-tolerated, with no treatment-related allergic adverse events (AEs) or treatment-related serious adverse events (SAEs) reported for either dose of PVX108.

Following a further six-month treatment-free period, a follow-up food challenge was conducted, which showed evidence of maintenance or improvement in clinical effects compared to month 12, suggesting the disease-modifying potential of PVX108.

PVX108 is an investigational, next-generation immunotherapy which uses peptides designed to precisely retrain the immune system to tolerate peanut whilst minimising treatment-induced acute allergic reactions. It has been awarded fast track designation from the US Food and Drug Administration (FDA) for the treatment of peanut allergy.

Dr Brian Vickery, chief of allergy and immunology at Children’s Healthcare of Atlanta and professor and vice-chair of Pediatric Clinical Research at Emory University School of Medicine, highlighted a critical need for these kinds of treatments in younger patients.

Vickery, who has served as an investigator on Aravax-sponsored studies, said: “Peanut allergy is a growing and serious problem for those living with allergies and their families. I am excited that this study has delivered compelling early evidence that PVX108 could deliver clinically meaningful impact in peanut allergy. These data show that once-monthly administration of PVX108 may offer the possibility of retraining the immune response to peanuts without burdensome precautions and, as such, have a longer-term positive impact on the course of allergic disease. If confirmed by larger studies, this would represent a significant leap forward for the food allergy field.”

Peanut allergy is one of the most common food allergies, with more than 1.6 million affected in the US. According to GlobalData analysis, the market size for peanut allergy was approximately $6.1bn in 2023, the most recent available data.

GlobalData is the parent company of Clinical Trials Arena.